Ceritinib-related interstitial lung disease improving after treatment cessation without recurrence under either crizotinib or brigatinib: a case report.

Anaplastic lymphoma kinase rearrangement (ALK rearrangement) ceritinib diffuse interstitial pneumonitis non-small cell lung cancer (NSCLC)

Journal

Annals of translational medicine
ISSN: 2305-5839
Titre abrégé: Ann Transl Med
Pays: China
ID NLM: 101617978

Informations de publication

Date de publication:
Mar 2019
Historique:
entrez: 26 4 2019
pubmed: 26 4 2019
medline: 26 4 2019
Statut: ppublish

Résumé

Anaplastic lymphoma kinase inhibitors (ALKi) like ceritinib are considered standard for front-line treatment of non-small cell lung cancers (NSCLC) harboring a translocation of the anaplastic lymphoma kinase (ALK) gene. We report herein a case of interstitial lung disease (ILD) that developed following a 7-month ceritinib treatment without recurrence under either crizotinib or brigatinib, two others ALKi.

Identifiants

pubmed: 31019956
doi: 10.21037/atm.2019.01.24
pii: atm-07-05-106
pmc: PMC6462648
doi:

Types de publication

Case Reports

Langues

eng

Pagination

106

Déclaration de conflit d'intérêts

Conflicts of Interest: B Mennecier and E Quoix were investigators of clinical trials regarding crizotinib, ceritinib, brigatinib and lorlatinib. The other authors have no conflicts of interest to declare.

Références

N Engl J Med. 2006 Dec 14;355(24):2542-50
pubmed: 17167137
N Engl J Med. 2010 Oct 28;363(18):1693-703
pubmed: 20979469
Clin Chest Med. 2011 Dec;32(4):605-44
pubmed: 22054876
J Clin Oncol. 2013 Jan 1;31(1):e15-7
pubmed: 23169500
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
N Engl J Med. 2014 Dec 4;371(23):2167-77
pubmed: 25470694
J Thorac Oncol. 2015 Aug;10(8):1148-55
pubmed: 26200268
Lancet. 2016 Apr 2;387(10026):1415-1426
pubmed: 26777916
Lancet Oncol. 2017 Jul;18(7):874-886
pubmed: 28602779
Lung Cancer (Auckl). 2017 Oct 13;8:169-177
pubmed: 29075144
Clin Lung Cancer. 2018 Mar;19(2):e151-e161
pubmed: 29174221
Lung Cancer. 2018 May;119:99-102
pubmed: 29656760
Ann Oncol. 2018 Jun 1;29(6):1409-1416
pubmed: 29668860
J Thorac Dis. 2018 Jun;10(6):3829-3844
pubmed: 30069384

Auteurs

Laura Bender (L)

Department of Medical Oncology, University Hospital, Strasbourg, France.

Guillaume Meyer (G)

Department of Pharmacy, University Hospital, Strasbourg, France.

Elisabeth Quoix (E)

Department of Pneumology, University Hospital, Strasbourg, France.

Bertrand Mennecier (B)

Department of Pneumology, University Hospital, Strasbourg, France.

Classifications MeSH